[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.157.225.99. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 20, 1969

Immunization Against InfluenzaPrevention of Illness in Man by Aerosolized Inactivated Vaccine

Author Affiliations

From the Department of Medicine, Division of Infectious Diseases, University of Florida, Gainesville (Drs. Waldman and Small); and the Department of Medicine, Johns Hopkins Medical School, Baltimore (Dr. Mann).

JAMA. 1969;207(3):520-524. doi:10.1001/jama.1969.03150160032007
Abstract

During the A2 influenza epidemic of the winter of 1967 to 1968, commercially available inactivated influenza virus vaccine, bivalent, was administered by aerosol to 386 volunteers to test its efficacy in protecting against influenza illness. The illness rate in volunteers receiving the aerosolized vaccine was compared to that of 269 persons receiving the same vaccine subcutaneously and to that of 1,490 persons who received either sodium chloride solution or no inoculation. The group receiving aerosolized influenza vaccine had 79% fewer illnesses while subcutaneously immunized volunteers had 27% fewer illnesses, when compared to the control groups receiving no immunization. In addition to its superiority in ability to protect against naturally occurring influenza illness, the aerosolized vaccine led to a significantly lower incidence of side effects and to a significantly shorter duration of illness in those few who became ill.

×